Press Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN Names Dr. William Stagner Senior Vice President, Program Management and Development Planning

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Dec. 8, 2004--POZEN Inc. (NASDAQ: POZN) announced today the appointment of William Stagner, R.Ph., Ph.D, an executive with 25 years of pharmaceutical development experience, as senior vice president, program management and development planning. Dr. Stagner will be responsible for management of the company's project development teams and programs.

"Bill is an outstanding pharmaceutical executive who brings to POZEN years of experience in the management of pharmaceutics, preclinical, and clinical development programs, as well as experience as a general manager," said Dr. John R. Plachetka, POZEN's chairman, president, and chief executive officer.

Dr. Stagner was most recently employed at Cardinal Health Pharmaceutical Development (formerly Magellan Labs) as senior vice president and general manager. Prior to joining Cardinal Health in 1999, Dr. Stagner held several executive positions at GlaxoWellcome, Inc., including group director, dermatology research and development, and pharmaceutics director for Glaxo Research Institute. Before joining Glaxo, Dr. Stagner was with Merrell Dow Research Institute.

During his tenure with Glaxo, Dr. Stagner was responsible for directing all dermatology product development activities for investigational and marketed products, as well as leading their discovery, preclinical, medical and regulatory efforts. While at Glaxo Research Institute and Cardinal Health he founded their pharmaceutics divisions. He has been on teams responsible for the approval of over 25 new drug applications (NDAs).

Dr. Stagner received his B.S., M.S., and Ph.D. degrees from the University of Iowa, College of Pharmacy.


POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. Since its inception, POZEN has focused its efforts primarily on the development of pharmaceutical products for the treatment of migraine. POZEN is also exploring the development of product candidates in other pain-related therapeutic areas. POZEN has development and commercial alliances with GlaxoSmithKline, Xcel Pharmaceuticals, and Nycomed. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website:

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval of our product candidates, including as a result of the need to conduct additional studies, or the failure to obtain such approval of our product candidates; uncertainties in clinical trial results or the timing of such trials, resulting in, among other things, an extension in the period over which we recognize deferred revenue or our failure to achieve milestones that would have provided us with revenue; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2004 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Chief Financial Officer
Bill Hodges
Director, Investor Relations
Fran Barsky


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.